- Home
- ENSC vs XBIO Comparison
ENSC vs XBIO Comparison
Compare ENSC & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- XBIO
- Stock Information
- Founded
- ENSC 2003
- XBIO N/A
- Country
- ENSC United States
- XBIO United States
- Employees
- ENSC N/A
- XBIO N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ENSC Health Care
- XBIO Health Care
- Exchange
- ENSC Nasdaq
- XBIO Nasdaq
- Market Cap
- ENSC 5.5M
- XBIO 5.8M
- IPO Year
- ENSC N/A
- XBIO N/A
- Fundamental
- Price
- ENSC $2.31
- XBIO $2.53
- Analyst Decision
- ENSC
- XBIO Hold
- Analyst Count
- ENSC 0
- XBIO 1
- Target Price
- ENSC N/A
- XBIO N/A
- AVG Volume (30 Days)
- ENSC 31.4K
- XBIO 7.1K
- Earning Date
- ENSC 05-12-2025
- XBIO 05-08-2025
- Dividend Yield
- ENSC N/A
- XBIO N/A
- EPS Growth
- ENSC N/A
- XBIO N/A
- EPS
- ENSC N/A
- XBIO N/A
- Revenue
- ENSC $5,210,031.00
- XBIO $2,500,284.00
- Revenue This Year
- ENSC N/A
- XBIO $14.23
- Revenue Next Year
- ENSC N/A
- XBIO N/A
- P/E Ratio
- ENSC N/A
- XBIO N/A
- Revenue Growth
- ENSC 133.58
- XBIO N/A
- 52 Week Low
- ENSC $2.12
- XBIO $2.26
- 52 Week High
- ENSC $14.67
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- ENSC 20.57
- XBIO 25.28
- Support Level
- ENSC $2.19
- XBIO $2.26
- Resistance Level
- ENSC $2.70
- XBIO $3.43
- Average True Range (ATR)
- ENSC 0.31
- XBIO 0.21
- MACD
- ENSC -0.05
- XBIO -0.07
- Stochastic Oscillator
- ENSC 5.26
- XBIO 16.67
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.